Christine Megerdichian Parseghian

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-2047-097X

发表论文 232 篇 · 总被引 1782 次 · h-index 22

代表论文

• Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors (2025 · Annals of Oncology · 被引 65)
• Mutational and co-mutational landscape of early onset colorectal cancer (2025 · Biomarkers · 被引 27)
• Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer (2025 · Cancer Cell · 被引 26)
• Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT (2025 · JCO Precision Oncology · 被引 6)
• 732MO Circulating tumour DNA (ctDNA) clearance and correlation with outcome in the INTERCEPT colorectal cancer (CRC) study (2025 · Annals of Oncology · 被引 4)
• BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy (2025 · npj Precision Oncology · 被引 4)